Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Inclusion criteria: * Signed and dated written informed consent * Male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) \> 1 year * C-peptide value of \< 0.7 ng/mL * Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total daily insulin \>= 0.3 and \<= 1.5 U/kg * Glycated haemoglobin (HbA1c) \>= 7.5% and \<= 10.0% * Good understanding of T1DM * Age \>= 18 years * Body Mass Index (BMI) \>= 18.5 kg/m2 * Estimated glomerular filtration rate \>= 30 mL/min/1.73 m2 * Women of child-bearing potential must use highly effective methods of birth control * Compliance with trial medication administration between 80% and 120% during placebo run-in period Further inclusion criteria apply Exclusion criteria: * History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis * Pancreas, pancreatic islet cells or renal transplant recipient * T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and bolus insulin within last 3 months * Occurrence of severe hypoglycaemia within last 3 months and until randomisation * Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6 * Irregular sleep/wake cycle * Acute coronary syndrome, stroke or Transient Ischaemic Attack (TIA) within last 3 months * Severe gastroparesis * Brittle diabetes * Liver disease * Eating disorders * Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen * Treatment with systemic corticosteroids * Change in dose of thyroid hormones within last 6 weeks and until randomisation * Cancer or treatment for cancer in the last five years * Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells * Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial * Alcohol or drug abuse * Intake of an investigational drug in another trial within last 30 days Further exclusion criteria apply